Wednesday, 14 October 2026European Markets
ExploreSearch
ViaNews EU
Source trace. Via News points to the documents behind its reporting and shows what we drew from each — so you can check any claim. How we source
Source document· March 5, 2026

Where's the beef? Fast food rivals challenge McDonald's to burger battle

View original at finance.yahoo.com
Where's the beef? Fast food rivals challenge McDonald's to burger battle McDonald's (MCD) CEO Chris Kempczinski has gone viral for how he took a bite out of the chain's new 1,200-calorie Big Arch burger in a recent video…
Opening lines of the source · short snapshot — read the full document at the original

What we drew from this source

The claims Via News extracted from this document. We point to the source; we don't replace it.

  • RFK Jr. might treat himself to yogurt during the Super Bowl as a snack

    80% confidence

  • The online attention is not bad publicity for McDonald's

    80% confidence

  • The chicken wars are done for now, beef is back

    80% confidence

  • Eating on camera is the worst thing anyone could ever do for themselves

    80% confidence

  • Wendy's should be terrified about McDonald's Big Arch launch given their double digit sales decline and lack of full-time CEO

    80% confidence

  • No issue with either Chris Kempczinski's bite execution or his discussion of the burger as a product

    80% confidence

  • People need to eat real food like giant ribs

    80% confidence

  • The Big Mac is the greatest sandwich ever invented

    80% confidence

  • McDonald's is a well run company

    80% confidence
What we know · the intelligence behind this page
Live from the substrate
What we're seeing
Q4 2026 Clinical Catalyst Season: Big-Pharma Data Flow, Regulatory Milestones, and a Thin AI-Drug Fringe
October 2026 conferences (EASD, IGCS, NACFC, HFSA) are producing a dense run of late-stage readouts from Novo Nordisk, Lilly, Roche, Bayer, Vertex and Galderma. Regulatory milestones are scheduled behind them: the ivonescimab BLA PDUFA date on 2026-11-14, FDA acceptance of Roche's vamikibart BLA, and Scholar Rock's EMA resubmission. The AI-and-finance angle is peripheral. It consists of the AI-designed drug Rentosertib and QAIAx, a speculative microcap whose trial claims (the QIII pilot, anticipated 2027-01-01, and a patent update) are forecasts and filings rather than data, so they warrant skepticism.
Our read on the data ›
Signals we're tracking
EPKINLY Regulatory-Clinical Success Cascade
High probability of expanded label indications, additional combination approvals, and competitive positioning strength in follicular lymphoma market. Predicts positive commercial uptake and potential accelerated review for related indications.
Patterns we're watching ›
Where sources disagree
ING Group
Both facts record the same metric (shares_outstanding) for ING Group at the identical observation date (2025-12-31). FACT A states 2,902,437,688 shares; FACT B states 2,902 million shares (2,902,000,000). The difference is 437,688 shares (~0.015%). This is a genuine value conflict, though the discrepancy appears to result from FACT B rounding to the nearest million while FACT A provides the precise count.
We flag conflicts openly ›
Recently verified
✓ Checked against the original source
4,986
facts traced to their source — and we flag the ones that don't hold up.
101 entities tracked4,986 facts checked against source5,375 source documents archived
Query this data → isubstrate.com
Where's the beef? Fast food rivals challenge McDonald's to burger battle — Source | Via News | ViaNews EU